What ALMIRALL HERMAL does

Almirall Hermal is the German operating subsidiary of Almirall S.A. (BME: ALM), a Barcelona-based, publicly-traded biopharmaceutical company founded in 1944 that has consolidated its focus on medical dermatology since divesting its respiratory franchise to AstraZeneca in 2014. The German subsidiary, headquartered in Reinbek near Hamburg, was acquired from Reckitt Benckiser in 2007 and operates the group's European manufacturing and marketing platform, employing ~300 of the parent group's 2,100+ global staff. Corporate research, drug discovery, and the headquarters function sit in Barcelona, with a global R&D centre at Sant Feliu de Llobregat.

The product portfolio spans biologics, small-molecule topicals, and OTC formulations addressing psoriasis, atopic dermatitis, actinic keratosis, acne, hidradenitis suppurativa, vitiligo, and rare dermatological conditions. Marketed assets include the biologics Ilumetri (tildrakizumab, anti-IL-23, €61.6M Q1 2026 net sales, +11.8% YoY) and Ebglyss (lebrikizumab, anti-IL-13, €41.9M Q1 2026 net sales, more than doubling YoY), the topicals Wynzora (calcipotriol/betamethasone) and Klisyri (tirbanibulin), German OTC brands Ciclopoli, Optiderm, Sililevo, and Selergo, and the neurology product Sativex. A pipeline of 14 projects (3 in Phase III) includes a first-in-class anti-IL-13/OX40L bispecific antibody (Phase I), an anti-IL-21 monoclonal antibody licensed from Novo Nordisk (NN-8828, Phase II, hidradenitis suppurativa), IL-2muFc in atopic dermatitis and alopecia areata, and ZKN-013 (a Phase I-ready nonsense mutation readthrough therapy licensed from Eloxx for epidermolysis bullosa). April 2026 brought an expanded framework with the Barcelona Supercomputing Center to apply AI and HPC to dermatology discovery.

Revenue is generated primarily through prescription pharmaceutical sales executed by a field force in 15 direct subsidiaries across Europe and the US (with distribution in 100+ countries), supplemented by OTC pharmacy sales in Germany and milestone/royalty income from out-licensed assets (Sun Pharma for tildrakizumab Europe rights, Lilly for lebrikizumab). FY2025 total revenue was €1,114.5 million, with €138.1 million (12.5% of net sales) invested in R&D. Commercial customers are dermatologists, GPs, and pharmacists; end users are patients with chronic skin conditions, and revenue is structurally diversified across geographies, molecules, and indications, with no single-customer concentration.

Name

ALMIRALL HERMAL

Legal name

Almirall Hermal GmbH

Website

https://almirall.de

Company type

Public

Founded year

1944

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Almirall Hermal is the German subsidiary of Barcelona-based Almirall S.A. (BME: ALM), a 1944-founded biopharmaceutical firm focused exclusively on medical dermatology, commercializing biologics, topicals, and OTC products across 100+ countries.

Ownership category

akta.pro rank

Product category

Medical Dermatology Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412)

SIC

Perfumes, Cosmetics & Other Toilet Preparations (2844)

akta.pro primary industry

Dermatology & Aesthetics Pharmaceuticals (HLAIAAAK)

akta.pro secondary industries

Dermatology Specialty Pharmaceuticals (HLAIACAL), Dermatology OTC & Skin Health (Acne Treatments, Eczema/Psoriasis OTC, Antifungals, Wart Removal) (CRADAMAF)

Keywords

• Medical dermatology pharmaceuticals
• Prescription biologics
• Topical dermatology treatments
• OTC skin care
• Pharmaceutical manufacturing

Headquarters

HQ city

Barcelona

HQ country

Spain

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Infrastructure, Operations

Revenue model

1. Prescription pharmaceuticals (Rx): Revenue from prescription-only medicines including biologics (tildrakizumab/Ilumetri, lebrikizumab/Ebglyss) and topical treatments for psoriasis, atopic dermatitis, actinic keratosis, acne, and nail disorders sold through healthcare professional prescriptions in Europe and the US.
2. Over-the-counter (OTC) products: Revenue from non-prescription products including OTC brands such as Ciclopoli, Optiderm, Sililevo, and Selergo sold through pharmacies and retail channels.
3. Licensing and milestone revenues: Revenue from out-licensing deals and milestone payments from partners such as Sun Pharma (tildrakizumab Europe rights) and Lilly (lebrikizumab), as well as potential future royalties from pipeline assets.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels7 records

Core offering

Almirall Hermal GmbH is the German pharmaceutical subsidiary of Almirall S.A. that develops, manufactures, and commercializes prescription and over-the-counter dermatology products. Its portfolio includes biologic drugs (Ilumetri for psoriasis, Ebglyss for atopic dermatitis), topical treatments (Wynzora, Klisyri), and OTC brands (Ciclopoli, Optiderm, Sililevo, Selergo) for conditions including psoriasis, atopic dermatitis, actinic keratosis, acne, and nail disorders. Products are manufactured at the Reinbek site near Hamburg and sold across more than 100 countries through 15 commercial subsidiaries.

Product overview

Almirall is a global pharmaceutical company dedicated to medical dermatology with a broad portfolio spanning prescription drugs, biologics, and OTC topical products. The company operates across two main therapeutic areas: dermatology (the primary focus) and neurology. In dermatology, the portfolio includes biologic drugs (Ilumetri® for psoriasis, Ebglyss® for atopic dermatitis), topical prescription drugs (Wynzora® for psoriasis, Klisyri® for actinic keratosis), and OTC brands (Ciclopoli®, Optiderm®, Sililevo®, Selergo®). The R&D pipeline includes multiple New Molecular Entities in various clinical phases targeting conditions such as hidradenitis suppurativa, atopic dermatitis, alopecia areata, inflammatory skin diseases, and rare dermatological conditions. In neurology, the company markets Sativex® for multiple sclerosis-induced spasticity.

Differentiator

Problem solved

Functional benefit

Brands

• AlmirallMed: Medical professional portal offering service materials, event information, and training offerings for healthcare professionals
• Almirall Innovation Hub The Hive
• Sanctuary Salon
• AlmirallShare
• Ciclopoli
• Optiderm
• Sililevo
• Selergo
• Ilumetri
• Ebglyss
• Wynzora
• Klisyri

Products and services

• Ilumetri® (Tildrakizumab) Monoclonal antibody (IgG1/κ humanized) targeting the IL-23 p19 subunit, indicated for the treatment of moderate-to-severe plaque psoriasis in adults. Sold under licensing agreement with Sun Pharma.
• Ebglyss® (Lebrikizumab) Immunoglobulin G4 monoclonal antibody targeting IL-13 with high affinity, indicated for moderate-to-severe atopic dermatitis in adults and adolescents aged 12+ weighing at least 40 kg. Commercialized in Europe under partnership with Eli Lilly.
• Wynzora® Topical combination of calcipotriol (vitamin D analog) and betamethasone dipropionate (corticosteroid) for treatment of mild to moderate plaque vulgaris psoriasis, including scalp psoriasis, in adults.
• Klisyri® (Tirbanibulin) Topical treatment for non-hyperkeratotic, non-hypertrophic actinic keratosis (Grade 1 Olsen) of the face or scalp in adults. Mechanism: disrupts microtubules via direct tubulin binding.
• Ciclopoli® OTC dermatology brand in Germany for treatment of nail conditions including onychomycosis (nail fungus). Distributed through pharmacy retail chains.
• Optiderm® OTC dermatology brand in Germany, part of Almirall Hermal's broad healthcare portfolio distributed through pharmacies.
• Sililevo® OTC dermatology brand in Germany, part of Almirall Hermal's portfolio distributed through pharmacy retail channels.
• Selergo® OTC dermatology brand in Germany, part of Almirall Hermal's consumer dermatology portfolio distributed through pharmacies.
• Sativex® Prescription product indicated for treatment of multiple sclerosis-induced spasticity. Represents Almirall's secondary presence in the neurology therapeutic area beyond its primary dermatology focus.
• NN-8828 (Anti-IL-21 Monoclonal Antibody) First-in-class high-affinity monoclonal antibody targeting IL-21 cytokine, in-licensed from Novo Nordisk. Being developed for immune inflammatory dermatological diseases including hidradenitis suppurativa, with potential to block downstream signaling pathways and inhibit pathophysiological functions in immune cells. Currently in Phase II development.
• ZKN-013 Phase I-ready oral nonsense mutation readthrough inducer for rare dermatological diseases including Recessive Dystrophic Epidermolysis Bullosa (RDEB), Junctional Epidermolysis Bullosa (JEB), and familial adenomatous polyposis (FAP). Licensed from Eloxx Pharmaceuticals.
• Anti-IL-13/OX40L Bispecific Antibody First-in-class bispecific monoclonal antibody simultaneously targeting IL-13 and OX40L, currently in Phase I clinical development for atopic dermatitis. Represents a novel mechanism for inflammatory skin disease treatment.
• IL-2muFc Immunomodulatory fusion protein (IL-2 mutant Fc) in Phase II development worldwide for inflammatory skin diseases, atopic dermatitis, and alopecia areata. Classified as a New Molecular Entity.

Quantifiable outcome

• 12.4% net sales growth in 2025, meeting full-year guidance
• +5 more outcomes

Named customers5 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature5 records

Partnerships

Eleven partnerships are on record, tiered core and minor.

• Barcelona Supercomputing Center (BSC)coreTechnology or Integration · 13 April 2026Strategic framework agreement expanding long-standing R&D collaboration to apply supercomputing, High-Performance Computing (HPC), and Artificial Intelligence to accelerate dermatology drug discovery. Almirall joins the BSC Connects program for access to personalized training, cutting-edge technologies, and co-developed R&D projects. Focus areas include genomics, digital twins, and drug design.
• Admit TherapeuticsminorStrategic or Co-development Partner · 4 December 2024Joined Almirall Innovation Hub The Hive as a new member. Admit Therapeutics focuses on early detection of Alzheimer's and other neurodegenerative diseases using technology combining epigenetic and clinical data with machine learning.
• MicroomicsminorStrategic or Co-development Partner · 4 December 2024Joined Almirall Innovation Hub The Hive as a new member. Microomics specializes in metagenomic analysis using new DNA sequencing technologies (NGS) for potential dermatology research applications.
• Eloxx PharmaceuticalscoreOEM/ Whitelabel/ Licensing Partner · 13 March 2024Exclusive global license agreement for ZKN-013, an oral nonsense mutation readthrough drug for rare dermatological diseases including Recessive Dystrophic Epidermolysis Bullosa (RDEB), Junctional Epidermolysis Bullosa (JEB), and familial adenomatous polyposis (FAP). Almirall receives global development and commercialization rights. Eloxx receives USD 3M upfront and up to USD 470M in milestones plus royalties.
• Novo NordiskcoreOEM/ Whitelabel/ Licensing Partner · 19 February 2024Exclusive global license agreement for NN-8828 (anti-IL-21 monoclonal antibody), a first-in-class biologic in dermatology. Almirall obtains worldwide rights to develop and commercialize the asset for immune inflammatory dermatological diseases including hidradenitis suppurativa. Novo Nordisk receives upfront, development and commercial milestones, and tiered royalties.
• Centrient PharmaceuticalsminorStrategic or Co-development Partner · 10 October 2023Initial partner in Almirall's open innovation centre (The Hive). Centrient Pharmaceuticals is a global leader in sustainable biosynthetic pharmaceutical products, collaborating with Almirall on manufacturing and research capabilities.
• ZeClinicsminorStrategic or Co-development Partner · 1 January 2023Initial partner in Almirall's open innovation centre (The Hive). ZeClinics is a Contract Research Organization (CRO) specializing in genetics research using zebrafish as a model organism for dermatology drug discovery.
• Sun PharmacoreOEM/ Whitelabel/ Licensing PartnerLicense agreement signed in 2016 for development and commercialization of tildrakizumab (Ilumetri) in Europe. Sun Pharma holds rights outside the US; Almirall commercializes the product across European markets.
• Eli Lilly (Lilly)coreStrategic or Co-development PartnerPartnership for lebrikizumab (Ebglyss). Lilly presented positive Phase 3 ADorable-11 trial results in pediatric and adolescent atopic dermatitis populations at AAD 2026. Almirall holds European commercialization rights and collaborates on lifecycle management and clinical trials including ADlong Phase 3b extension (4-year efficacy data presented at AAD 2026).
• SIMCEREminorStrategic or Co-development PartnerPartner conducting atopic dermatitis trial for IL-2muFc molecule in China (Worldwide ex-Greater China), supporting Almirall's global development strategy for inflammatory skin disease indications.
• Pharmaceutical Supply Chain Initiative (PSCI)minorOthersAlmirall is a member of PSCI, committed to fostering sustainability in the pharmaceutical industry supply chain. The company supports PSCI principles for responsible supply chain management and audits suppliers for alignment.

Scale indicators10 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• AbbVie: Markets Skyrizi (risankizumab, IL-23) and Rinvoq (upadacitinib, JAK) across psoriasis, psoriatic arthritis and atopic dermatitis - directly competing with Ilumetri and Ebglyss. Broad incumbent in immunology with global dermatology commercial infrastructure.
• Novartis: Cosentyx (secukinumab, IL-17A) is a leading biologic in psoriasis and competes with Almirall's Ilumetri across moderate-to-severe indications. Broad incumbent with significant dermatology and immunology commercial reach.
• Sanofi (Regeneron partnership): Dupixent (dupilumab) is the market-leading IL-4/IL-13 biologic for atopic dermatitis and a direct competitor to Almirall's Ebglyss (lebrikizumab). Broad incumbent with large dermatology, immunology and rare disease franchises and significant commercial firepower.
• Bristol Myers Squibb: Sotyktu (deucravacitinib, TYK2) is approved for moderate-to-severe plaque psoriasis, positioning BMS as a new entrant in IL-pathway dermatology that competes with Almirall's psoriasis franchise. Broad incumbent with global immunology footprint.

Others

• Sun Pharmaceutical Industries: Out-licensor of tildrakizumab (Ilumetri) to Almirall for European rights. Global specialty/generic pharma with its own dermatology and biologics presence in the US; peer given economic linkage through tildrakizumab and overlapping dermatology portfolio in India and emerging markets.
• Eli Lilly: Licensing partner for lebrikizumab (Ebglyss), with which Almirall co-develops the atopic dermatitis franchise. Included as a peer given its emerging dermatology/immunology presence (lebrikizumab, mirikizumab in IBD/psoriasis-adjacent indications) and joint clinical lifecycle ownership.

Direct peers

• LEO Pharma: Privately-held Danish specialty pharma dedicated to dermatology, with a portfolio spanning psoriasis, atopic dermatitis, actinic keratosis and skin infections. Direct peer given shared dermatology-only strategic focus, European HQ, and overlapping prescription/OTC business model.
• Galderma: Privately-held dermatology-focused specialty pharma with a prescription and aesthetic dermatology portfolio. Most direct peer to Almirall given shared focus on medical dermatology across biologics, topicals and aesthetics, overlapping indications (acne, psoriasis, atopic dermatitis) and comparable European heritage.

Emerging players

• Incyte: Markets Opzelura (ruxolitinib cream) for atopic dermatitis and vitiligo - a JAK inhibitor topical competing with Almirall's Wynzora and Klisyri in adjacent dermatoses. Smaller specialty player with growing dermatology presence relevant to Almirall's topical franchise.
• Arcutis Biotherapeutics: US dermatology-focused biotech with Zoryve (roflumilast) cream and foam for psoriasis, seborrheic dermatitis and atopic dermatitis. Emerging peer in medical dermatology competing with Almirall's topical portfolio in similar inflammatory skin indications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/channel/UCntS40DsPAXEoIyufV4xC_g
• LinkedInlinkedin.com/company/almirall
• Xx.com/almirallus

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ALMIRALL HERMAL